Want to see OBIO full AI Analyst Report?
Top Page
Orchestra BioMed Holdings
(NASDAQ:OBIO)
Select Model
Select Model
Rating:59Neutral
Price Target:
$6.00
▲(11.94% Upside)
Action:Reiterated
Date:10/01/26
OBIO’s score is held back primarily by large ongoing losses and substantial cash burn despite strong recent revenue scale-up and high gross margins. Offsetting this, the stock shows solid technical uptrend/momentum, and recent corporate milestones (pivotal trial full enrollment and program progress) provide positive near-term catalysts. Valuation remains constrained by unprofitability and lack of dividend support.
Positive Factors
High-margin revenue scale
Revenue has scaled materially from roughly $2–4 million in 2022–2024 to more than $32 million recently, while gross margins remain near 99%. This indicates a potentially valuable partnership revenue stream that can support future investment as programs advance.
Negative Factors
Persistent unprofitability
Despite the sharp revenue increase, OBIO remains deeply unprofitable, showing that operating expenses are still far ahead of its current revenue base. Continued losses could delay self-funded expansion and require additional financing before the pipeline generates recurring commercial income.
Read all positive and negative factors
Positive Factors
Negative Factors
High-margin revenue scale
Revenue has scaled materially from roughly $2–4 million in 2022–2024 to more than $32 million recently, while gross margins remain near 99%. This indicates a potentially valuable partnership revenue stream that can support future investment as programs advance.
Read all positive factors
Orchestra BioMed Holdings (OBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$357.63M
Dividend YieldN/A
Average Volume (3M)331.56K
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue Growth986.14%
EPS Growth45.31%
CountryUS
Employees86
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.99
Shares Outstanding60,105,050
10 Day Avg. Volume273,270
30 Day Avg. Volume331,560
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.13
Price to Sales (P/S)5.92
P/FCF Ratio-4.01
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue7.70
Enterprise Value/Gross Profit7.75
Enterprise Value/Ebitda-4.31
Forecast
1Y Price Target
$11.20Price Target Upside108.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.52
Revenue Forecast (FY)$448.29K
Orchestra BioMed Holdings Business Overview & Revenue Model
Company Description
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion ...
How the Company Makes Money
Orchestra BioMed’s business model is centered on monetizing its device-therapy programs through strategic collaborations rather than building a large, fully integrated commercial sales infrastructure on its own. Its revenue (when generated) can co...
Orchestra BioMed Holdings Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.98M | 33.48M | 2.64M | 2.76M | 3.53M | -782.00K |
| Gross Profit | 31.76M | 33.29M | 2.43M | 2.57M | 3.21M | -981.00K |
| EBITDA | -57.10M | -51.23M | -60.72M | -48.83M | -33.39M | -21.91M |
| Net Income | -59.03M | -52.70M | -61.02M | -49.12M | -33.61M | -23.01M |
Balance Sheet | ||||||
| Total Assets | 115.70M | 114.86M | 76.17M | 95.21M | 95.57M | 13.53M |
| Cash, Cash Equivalents and Short-Term Investments | 109.96M | 106.51M | 66.81M | 87.59M | 83.78M | 10.90M |
| Total Debt | 70.76M | 15.96M | 16.53M | 1.69M | 11.87M | 5.67M |
| Total Liabilities | 86.28M | 51.48M | 43.22M | 27.17M | 43.04M | 84.76M |
| Stockholders Equity | 29.42M | 63.38M | 32.96M | 68.04M | 52.53M | -71.23M |
Cash Flow | ||||||
| Free Cash Flow | -59.10M | -49.45M | -50.85M | -46.20M | -29.88M | -19.70M |
| Operating Cash Flow | -58.32M | -48.96M | -50.56M | -46.13M | -29.29M | -19.43M |
| Investing Cash Flow | -69.29M | -26.94M | 13.09M | 10.69M | -64.12M | 13.02M |
| Financing Cash Flow | 129.33M | 88.33M | 29.17M | 46.22M | 103.26M | -3.99M |
Orchestra BioMed Holdings Technical Analysis
Positive
5.36
Price Trends
5.35
Positive
4.65
Positive
4.44
Positive
Market Momentum
0.14
Positive
54.61
Neutral
23.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Positive. The current price of 5.36 is below the 20-day moving average (MA) of 5.99, above the 50-day MA of 5.35, and above the 200-day MA of 4.44, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 54.61 is Neutral, neither overbought nor oversold. The STOCH value of 23.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OBIO.
Orchestra BioMed Holdings Risk Analysis
Orchestra BioMed Holdings disclosed 81 risk factors in its most recent earnings report. Orchestra BioMed Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orchestra BioMed Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $357.63M | -6.01 | -125.93% | ― | 986.14% | 45.31% | |
52 Neutral | $631.80M | -13.25 | -31.79% | ― | ― | -19.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $84.02M | -1.80 | -103.08% | ― | -6.96% | 32.77% | |
49 Neutral | $242.50M | -1.44 | -215.23% | ― | 291.42% | 11.70% | |
48 Neutral | $83.39M | -4.57 | -50.17% | ― | ― | 70.27% |
* Healthcare Sector Average
OBIO
Orchestra BioMed Holdings
5.95
2.76
86.52%
CRDF
Cardiff Oncology
1.08
-1.18
-52.21%
GLSI
Greenwich LifeSciences
16.53
6.23
60.49%
CLYM
Climb Bio
11.00
9.00
450.00%
CGTX
Cognition Therapeutics
0.88
-0.92
-51.33%
PYXS
Pyxis Oncology
2.03
-1.42
-41.16%
Orchestra BioMed Holdings Corporate Events
Business Operations and Strategy
Orchestra BioMed Completes Enrollment in BACKBEAT AVIM Trial
Positive
Oct 1, 2026
On Oct. 1, 2026, Orchestra BioMed reported that its BACKBEAT global pivotal trial of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension had surpassed full enrollment. As of Sept. 30, 2026, 330 patients were randomized at 8...
Business Operations and Strategy
Orchestra BioMed Highlights Pivotal Cardiovascular Program Progress
Positive
Sep 8, 2026
In September 2026, Orchestra BioMed released a corporate slide presentation highlighting its progress and strategy as it advances pivotal-stage cardiovascular programs in collaboration with large device companies. The presentation, now available t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.